EA201590794A8 - Рекомбинантные нейротоксины clostridium botulinum - Google Patents

Рекомбинантные нейротоксины clostridium botulinum

Info

Publication number
EA201590794A8
EA201590794A8 EA201590794A EA201590794A EA201590794A8 EA 201590794 A8 EA201590794 A8 EA 201590794A8 EA 201590794 A EA201590794 A EA 201590794A EA 201590794 A EA201590794 A EA 201590794A EA 201590794 A8 EA201590794 A8 EA 201590794A8
Authority
EA
Eurasian Patent Office
Prior art keywords
contiguous nucleotides
bont
clostridium botulinum
sequence
stranded
Prior art date
Application number
EA201590794A
Other languages
English (en)
Other versions
EA201590794A1 (ru
Inventor
Эйми Коссинс
Мэттью Биэрд
Маркс Филип
Original Assignee
Синтаксин Лимитед
Ипсен Байофарм Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синтаксин Лимитед, Ипсен Байофарм Лимитед filed Critical Синтаксин Лимитед
Publication of EA201590794A1 publication Critical patent/EA201590794A1/ru
Publication of EA201590794A8 publication Critical patent/EA201590794A8/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Изобретение относится к последовательности нуклеиновой кислоты, содержащей последовательность смежных нуклеотидов, где указанная последовательность смежных нуклеотидов обладает по меньшей мере 90% идентичностью последовательности нуклеиновой кислоты SEQ ID NO: 1 и где указанная последовательность смежных нуклеотидов кодирует одноцепочечный белок BoNT/E1. Изобретение также относится к способам получения растворимого одноцепочечного белка BoNT/E в клетке-хозяине Е.coli вместе со способами получения растворимого двухцепочечного белка BoNT/E1.
EA201590794A 2012-10-31 2013-10-31 Рекомбинантные нейротоксины clostridium botulinum EA201590794A8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (2)

Publication Number Publication Date
EA201590794A1 EA201590794A1 (ru) 2015-08-31
EA201590794A8 true EA201590794A8 (ru) 2016-01-29

Family

ID=47358958

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590794A EA201590794A8 (ru) 2012-10-31 2013-10-31 Рекомбинантные нейротоксины clostridium botulinum

Country Status (27)

Country Link
US (1) US10030238B2 (ru)
EP (3) EP3673914B1 (ru)
JP (2) JP2019068823A (ru)
KR (2) KR102188539B1 (ru)
CN (2) CN104755098A (ru)
AR (2) AR093309A1 (ru)
AU (3) AU2013340610B2 (ru)
BR (1) BR112015005384A2 (ru)
CA (1) CA2885519A1 (ru)
DK (2) DK2914282T3 (ru)
EA (1) EA201590794A8 (ru)
ES (2) ES2788199T3 (ru)
GB (1) GB201219602D0 (ru)
HK (1) HK1208359A1 (ru)
HU (2) HUE036764T2 (ru)
IL (1) IL237623B (ru)
IN (1) IN2015MN00436A (ru)
MX (2) MX367080B (ru)
NO (1) NO2914282T3 (ru)
NZ (1) NZ705575A (ru)
PL (2) PL3326644T3 (ru)
PT (2) PT3326644T (ru)
SG (2) SG11201502372SA (ru)
TW (3) TWI673361B (ru)
UA (1) UA118837C2 (ru)
WO (1) WO2014068317A1 (ru)
ZA (1) ZA201501449B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
PT3274364T (pt) * 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
CA3010146A1 (en) 2016-03-02 2017-09-08 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
CN110072880A (zh) 2016-08-24 2019-07-30 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
JP7229247B2 (ja) * 2018-01-29 2023-02-27 イプセン バイオファーム リミテッド 非ニューロンｓｎａｒｅ切断性ボツリヌス神経毒
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
EP1119626B1 (en) 1998-07-10 2008-01-02 U.S. Army Medical Research Institute of Infectious Diseases Botulinum neurotoxin vaccine
EP2267009B1 (en) 1999-08-25 2014-10-29 Allergan, Inc. Activatable recombinant neurotoxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
AU2005327457B2 (en) * 2003-09-25 2012-08-23 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20110111483A1 (en) * 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
WO2008008082A2 (en) * 2005-09-19 2008-01-17 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
JP2009543558A (ja) * 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
KR20160103551A (ko) 2008-12-10 2016-09-01 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
EP2419128B1 (en) * 2009-04-14 2018-06-06 Medical College of Wisconsin, Inc. Engineered botulinum neurotoxin
KR20120107988A (ko) * 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
US20120207743A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
CN110072880A (zh) * 2016-08-24 2019-07-30 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素

Also Published As

Publication number Publication date
ES2662402T3 (es) 2018-04-06
HUE036764T2 (hu) 2018-07-30
TW201435084A (zh) 2014-09-16
EP3326644A1 (en) 2018-05-30
CN104755098A (zh) 2015-07-01
TWI673361B (zh) 2019-10-01
CN110499321A (zh) 2019-11-26
HK1208359A1 (en) 2016-03-04
MX2019009222A (es) 2019-11-21
EP3673914B1 (en) 2021-10-27
KR102264478B1 (ko) 2021-06-15
AU2018203556A1 (en) 2018-06-07
JP2020078321A (ja) 2020-05-28
AU2018203556B2 (en) 2020-08-20
EP2914282A1 (en) 2015-09-09
IL237623A0 (en) 2015-04-30
US20150247139A1 (en) 2015-09-03
EA201590794A1 (ru) 2015-08-31
EP2914282B1 (en) 2017-12-20
UA118837C2 (uk) 2019-03-25
KR102188539B1 (ko) 2020-12-09
CA2885519A1 (en) 2014-05-08
PT3326644T (pt) 2020-05-29
AU2013340610A1 (en) 2015-03-19
EP3673914A1 (en) 2020-07-01
SG11201502372SA (en) 2015-05-28
KR20200110470A (ko) 2020-09-23
AU2013340610B2 (en) 2018-02-22
PL3326644T3 (pl) 2020-08-24
HUE048802T2 (hu) 2020-08-28
AR093309A1 (es) 2015-05-27
PL2914282T3 (pl) 2018-07-31
TW201825680A (zh) 2018-07-16
KR20150094590A (ko) 2015-08-19
GB201219602D0 (en) 2012-12-12
DK2914282T3 (en) 2018-02-26
MX367080B (es) 2019-08-05
ZA201501449B (en) 2016-08-31
NZ705575A (en) 2019-08-30
SG10201701140WA (en) 2017-04-27
PT2914282T (pt) 2018-03-13
JP2019068823A (ja) 2019-05-09
WO2014068317A1 (en) 2014-05-08
IN2015MN00436A (ru) 2015-09-04
TWI626307B (zh) 2018-06-11
US10030238B2 (en) 2018-07-24
TW202012622A (zh) 2020-04-01
EP3326644B1 (en) 2020-03-04
MX2015005156A (es) 2015-09-23
AU2020244481A1 (en) 2020-10-29
AR117738A2 (es) 2021-08-25
ES2788199T3 (es) 2020-10-20
BR112015005384A2 (pt) 2017-08-08
IL237623B (en) 2019-05-30
NO2914282T3 (ru) 2018-05-19
DK3326644T3 (da) 2020-05-11

Similar Documents

Publication Publication Date Title
EA201590794A8 (ru) Рекомбинантные нейротоксины clostridium botulinum
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
WO2014202616A3 (en) Rasamsonia gene and use thereof
MX2015017110A (es) Integracion dirigida.
EA201291024A1 (ru) Композиции эндорибонуклеаз и способы их использования
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
BR112017022322A2 (pt) enzimas e aplicações das mesmas
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
MX2014004598A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2014202622A3 (en) Rasamsonia gene and use thereof
EA201300056A1 (ru) Полипептид с активностью ацетилксиланэстеразы и его применения
IN2015DN03206A (ru)
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.
MX2018004392A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
MX2014007446A (es) Variantes de subtilasa y polinucleotidos que las codifican.
IN2015DN01042A (ru)
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
MY171359A (en) Pentose fermenting microorganisms
BR112017009515A8 (pt) Fitase, método para obter a mesma e uso do mesmo
WO2014202623A3 (en) Rasamsonia gene and use thereof